Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (prognox) in murine and xenograft systems in vivo

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 731-735

  Honess, Davina J ^a   Hill, Sally A ^a   Collingridge, David R ^a   Edwards, Barbara ^b   Brauers, Georg ^b   Powell, Nigel A ^b   Chaplin, David J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b GENERAL ELECTRIC COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXIME DERIVATIVE; RADIOLIGAND; TECHNETIUM 99M; UNCLASSIFIED DRUG; UPENAZIME; UPENAZIME TC 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYPOXIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; TISSUE OXYGENATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CARBON DIOXIDE; CARCINOMA; CELL HYPOXIA; COLONIC NEOPLASMS; CONTRAST MEDIA; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED CBA; MICE, SCID; NIACINAMIDE; ORGANOTECHNETIUM COMPOUNDS; OXIMES; OXYGEN; RADIOPHARMACEUTICALS; SARCOMA;

EID: 0031793733     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00300-9     Document Type: Conference Paper

References (10)

1. Coleman C.N. Hypoxia in tumours a paradigm for the approach to biochemical and physiologic heterogeneity . J Natl Cancer Inst. 80:1988;310-317.
2. Höckel M., Vorndran B., Schlenger K., Bauβmann E., Knapstein P.G. Tumor oxygenation a new predictive parameter in locally advanced cancer of the uterine cervix . Gynecol Oncol. 51:1993;141-149.
3. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:1996;31-39.
4. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
5. Chapman J.D., Engelhardt E.L., Stobbe C.C., Schneider R.F., Hanks G.E. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 46:1998;229-237.
6. Archer C.M., Edwards B., Kelly J.D., King A.C., Burke J.F., Riley A.L.M. Technetium labelled agents for imaging tissue hypoxia in vivo. Nicolini M., Bandoli G., Mazzi U. Technetium and rhenium in chemistry and nuclear medicine. 1995;535-539 SG Editoriali, Padua, Italy.
7. Chaplin D.J., Horsman M.R., Trotter M.J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour. J Natl Cancer Inst. 82:1990;672-676.
8. Honess D.J., Bleehen N.M. Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer. 74:1995;1175-1180.
9. Powell M.E.B., Hill S.A., Saunders M.I., Hoskin P.J., Chaplin D.J. The effect of carbogen breathing on tumour microregional blood flow in human. Radiother Oncol. 39:1996;235-241.
10. Chaplin D.J., Horsman M.R., Siemann D.W. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo; importance of nicotinamide dose and pre-irradiation breathing time. Br J Cancer. 68:1993;269-273.